Highly effective direct antiviral agents (DAAs) for hepatitis C virus (HCV) were introduced recently. Their utilisation has been limited by high cost and low access to care.
SUMMARY Background
Highly effective direct antiviral agents (DAAs) for hepatitis C virus (HCV) were introduced recently. Their utilisation has been limited by high cost and low access to care.
Aim
To describe the effect of DAAs on HCV treatment and cure rates in the United States Veterans Affairs (VA) national healthcare system.
Methods
We identified all HCV antiviral treatment regimens initiated from 1 January 1999 to 31 December 2015 (n = 105 369) in the VA national healthcare system, and determined if they resulted in sustained virological response (SVR).
Results HCV antiviral treatment rates were low (1981-6679 treatments/year) in the interferon era (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) . The introduction of simeprevir and sofosbuvir in 2013 and ledipasvir/sofosbuvir and paritaprevir/ombitasvir/ritonavir/dasabuvir in 2014 were followed by increases in annual treatment rates to 9180 in 2014 and 31 028 in 2015. The number of patients achieving SVR was 1313 in 2010, the last year of the interferon era, and increased 5.6-fold to 7377 in 2014 and 21-fold to 28 084 in 2015. The proportion of treated patients who achieved SVR increased from 19.2% in 1999 and 36.0% in 2010 to 90.5% in 2015. Within 2015, monthly treatment rates ranged from 727 in July to 6868 in September correlating with the availability of funds for DAAs.
Conclusions
DAAs resulted in a 21-fold increase in the number of patients achieving HCV cure. Treatment rates in 2015 were limited primarily by the availability of funds. Further increases in funding and cost reductions of DAAs in 2016 suggest that the VA could cure the majority of HCV-infected Veterans in VA care within the next few years.
INTRODUCTION
Interferon-based antiviral regimens used to treat hepatitis C virus (HCV) infection until 2011 had low response rates, long duration, multiple side effects and several contraindications to treatment. These factors limited the number of HCV-infected patients who received treatment and even more so the number who achieved eradication of HCV, known as 'sustained virological response' (SVR). Only an estimated 5-6% of all HCV-infected persons in the United States attained SVR in the interferon era. 1 A number of direct-acting antiviral agents (DAAs) for HCV have been introduced since 2011, starting with boceprevir and telaprevir, which were used in combination with interferon and ribavirin. Highly effective, interferon-free regimens became available with the introduction of simeprevir and sofosbuvir in November and December 2013 and ledipasvir/sofosbuvir (LDV/ SOF) and paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD) in October and December 2014. Clinical trials of LDV/SOF and PrOD reported SVR rates exceeding 95% with well-tolerated regimens as short as 8-12 weeks in genotype 1-infected patients. [2] [3] [4] [5] [7] [8] [9] The availability of DAAs raised hopes of dramatically improving HCV treatment and cure rates within the United States. 10 However, treatment rates were limited by the high costs of the antiviral agents, variable coverage by medical insurance companies, limited access to HCV treatment providers and inadequate clinical capacity to treat large numbers of HCV-infected patients. Furthermore, until recently, almost all payers incorporated eligibility or prioritisation criteria, restricting access or prioritising those HCV-infected patients with advanced liver fibrosis, cirrhosis or extrahepatic manifestations of HCV. The VA healthcare system is the largest provider of care for chronic HCV infection in the United States. 11 In 2013, there were 174 302 patients with diagnosed HCV infection in VA care and an additional estimated 45 000 patients with undiagnosed HCV. 12 We sought to determine the impact of the new DAAs on HCV treatment and cure rates in the United States Veterans Affairs (VA) healthcare system by comparing these annual rates before and after the introduction of DAAs. On 31 July 2015, the US Congress appropriated an additional $500 million in 'unrestricted' funding for HCV DAAs to be used only in August and September 2015. 13 Therefore, we additionally examined monthly treatment rates during this time to assess the VA's capacity to treat large numbers of HCV-infected patients if funding for DAAs or prioritisation criteria were not limiting factors. We believe that our findings based on the VA healthcare system might be relevant and informative for other comprehensive healthcare systems.
METHODS

Data source
The Veterans Health Administration is the largest integrated healthcare system in the United States. It includes 154 medical centres and 875 ambulatory care and community-based outpatient clinics throughout the country. In 2013, 5 720 614 Veterans received VA healthcare. 14 We extracted electronic medical records on all patients who received antiviral treatment from 1999 to 2015 using the VA Corporate Data Warehouse (CDW). The CDW is a national, continually updated repository of data from the VA's computerised patient records, 15 including pharmacy prescriptions, patient demographics and clinical data for both inpatient and outpatient visits.
Study population and baseline characteristics
We identified all HCV antiviral regimens (n = 105 369 regimens among 78 947 patients) initiated in the VA during a 17-year period from 1 January 1999 to 31 December 2015. For each HCV treatment regimen, we collected baseline data including age, sex, HCV genotype, pre-treatment HCV viral load, laboratory tests and prior receipt of antiviral treatment. We also determined the presence of cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, depression, PTSD, anxiety/panic disorder, bipolar disease and schizophrenia based on ICD-9 codes, previously validated in the VA medical records, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] recorded at least twice prior to treatment initiation in any inpatient or outpatient encounter (Table S1) . For all patients, data extended backwards to 1 October 1998 to allow the determination of previous antiviral treatments and medical history and forward until 15 April 2016 to allow completion of treatments and ascertainment of SVR.
Ascertainment of sustained virological response (SVR)
We defined SVR as a serum HCV RNA viral load below the lower limit of quantification at least 12 weeks after the end of HCV treatment. 27 given their dramatic differences in regimens and SVR rates. The number of imputations was varied from 50 to 200 resulting in estimates that were identical up to four significant digits. The model was determined to be stable and an m = 50 imputations was used. Data were assumed to be missing at random. This assumption was found to be reasonable using the observed data. Interrupted time series (ITS) analysis of trends was used to determine whether trends in treatment or cure rates that occurred after the introduction of different antiviral agents or after major funding increases were significantly different than the trend that would be expected if these changes were not introduced. The intervention impact effect was assumed to be both a level and slope change. Because of the count nature of the data, a Poisson regression model was selected. Over-dispersion was addressed by allowing variance to be proportional to the mean. Seasonality and auto-correlation were adjusted for using Fourier terms consisting of pairs of sine and cosine functions.
Analyses were performed using STATA/MP version 14 (StataCorp, College Station, TX, USA).
Role of funding source
The study was funded by the VA's Office of Research and Development, which had no role in the study's design, conduct or reporting.
RESULTS
Baseline characteristics of antiviral treatment recipients and their trends Among 78 947 patients who initiated 105 369 regimens from 1999 to 2015, the average age was 56.2 AE 7.7 years, 96.8% were male, 61.7% were white, 29.3% were black, 79.2%/12.0%/8.0%/0.8% had HCV genotypes 1/2/3/4, respectively, 21.5% had cirrhosis, 6.6% had decompensated cirrhosis and 1.7% had HCC before the treatment initiation (Table 1) . Noteworthy trends over time from 1999 to 2015, included a steady increase in age (51.1-61.2 years) and the proportion of black patients (24.4%-36.7%). There was also an increase in the proportion of patients with cirrhosis, decompensated cirrhosis and HCC, which peaked in 2014 before declining in 2015.
Trends in annual treatment rates, 1999-2015 Annual treatment rates more than doubled from 2726 in 2001 to 6679 in 2002, the year after the introduction of pegylated-interferon ( Figure 1 and Table S2 ). During the pegylated-interferon era (2001-2010), annual treatment rates peaked at 6679 in 2002 followed by a steady decline until 2010. The introduction of boceprevir and telaprevir in 2011, which had to be used in combination with pegylated-interferon and ribavirin, led to a modest increase in annual treatments to 4900 in 2012. This was followed by a reduction in annual number of treatments to 2609 in 2013, the lowest number since 2000. The introduction of sofosbuvir and simeprevir at the end of 2013, was followed by a dramatic increase in annual treatments to 9180 in 2014 followed by a larger increase to 31 028 in 2015 after the introduction of LDV/SOF and PrOD.
Trends in annual treatment rates among traditionally 'Difficult-to-Treat' subgroups Increases in annual treatment rates that occurred between the end of the pegylated-interferon era in 2010 and 2015 were even more pronounced among patients with cirrhosis (13.4-fold increase), decompensated cirrhosis (14.3-fold increase), genotype 1 HCV (11.3-fold increase), hepatocellular carcinoma (20.6-fold increase) and age >60 years (28.5-fold increase) compared with an 8.5-fold increase among all patients ( Figure 2 and Table S3 ).
Annual trends in SVR rates SVR rates (observed or imputed) increased progressively from <25% in the regular interferon era Table S4 ). These increases in SVR rates were even more pronounced in traditionally 'difficult-to-treat' patients such as those with cirrhosis (from 11.0 to 87.0%), decompensated cirrhosis (from 14.6 to 85.2%), treatment-experienced patients (from 16.4 to 89.3%) and genotype 1-infected patients (from 1.3 to 91.7%). The gap in SVR rates between these difficult-to-treat populations and treatment na€ ıve (91.3%) and noncirrhotic patients (92.2%) was mostly bridged by 2015 ( Figure 3b and Tables S5 and S6 ). Impact of funding availability on antiviral treatment rates In fiscal year (FY) 2015, which spanned October 2014 to September 2015, the VA allocated $696 million to offset the costs of HCV DAAs. 28 We observed a nine-fold fluctuation in monthly treatment rates during FY 2015. This seemed to correlate mostly with the availability of funds for DAAs (Figure 4 ). Monthly rates increased rapidly from 1135 treatments/month in October 2014, when LDV/SOF and PrOD became FDA approved, to 3413 treatments/month in March 2015. This was followed by ]. † Race/Ethnicity and HCV Genotype are shown as proportions among those with available data. A small number had missing data as shown in Table S3 . Several factors likely contributed to the remarkable increases in HCV treatment and cure rates that occurred in 2014 and 2015. Most importantly, the introduction of interferon-free DAAs vastly increased the VA population eligible for and willing to undergo antiviral treatment. Second, given the high relative cost of DAAs, increases in the VA funding were critical. Third, the VA embraced innovative care models including the use of teleconsultation for HCV treatment. 30 Through the Specialty Care
Annual trends in number of patients achieving SVR
Access Network-Extension for Community Healthcare Outcomes (SCAN-ECHO) program, which allows physicians, nurses and pharmacists to get teaching and feedback through videoconferencing from HCV experts, median time from diagnosis to treatment has decreased from more than 2 years to 6 months. 31 Finally, the VA used existing electronic databases to identify and coordinate care for HCV-infected Veterans, employed aggressive screening practises for HCV and encouraged local facilities to set ambitious treatment goals. These goals were facilitated by a national integrated hepatitis C program, which oversees and supports dedicated hepatitis C teams at every VA facility. 32 Although a record number of highly effective antiviral regimens were prescribed in 2015 (n = 31 028), this still represented only a small proportion of all HCV-infected patients in the VA care. The number of patients who received HCV antiviral treatment could, in theory, be limited by the availability of funds for DAAs, the cost of DAAs, access to experienced treatment providers, identification and linkage to care of eligible HCV-infected patients and willingness of patients to undergo treatment. The nine-fold variation in monthly treatment rates in FY 2015 related to availability of DAA funding suggests that funding for HCV treatment was the most important determinant of treatment rates in 2015 (Figure 4) . Whilst the increases in HCV treatment and cure rates in 2014 and 2015 were impressive, there are reasons to believe that these rates will increase even further in 2016. First, in January 2016, the US Congress approved $1.5 billion for HCV DAA costs in the VA in FY 2016, doubling the funding from FY 2015.
33 Second, the VA was able to purchase LDV/SOF and PrOD in 2016 at approximately half the price paid in 2015. 31, 34 Third, the FDA approval of additional antiviral agents including daclatasvir (approved 24 July 2015), elbasvir/grazoprevir (approved 28 January16) and velpatasvir/sofusbuvir (approved 28 June 2016) will lead to increased treatment and cure rates, particularly for genotype 2 and 3-infected patients who have fewer treatment options and lower SVR rates than genotype 1-infected patients. Finally, the VA employed prioritisation criteria until February 2016, encouraging facilities and providers to give priority to the treatment of patients with advanced fibrosis or cirrhosis, those likely to have rapid progression of fibrosis and those with extrahepatic manifestations of HCV. 35 However, as of February 2016, the VA removed all HCV treatment prioritisation criteria and encouraged treatment of all patients, whilst continuing to emphasise aggressive outreach to patients with advanced fibrosis or cirrhosis. 36 This should further increase treatment rates and is in stark contrast to most healthcare systems, state Medicaid programs and insurance carriers in the US, which still restrict access to DAAs based on severity of liver disease. Following the VA's lead, state Medicaid programs in New York, Washington, Delaware, Florida and Massachusetts announced the removed restrictions on the coverage of DAAs. Also the AASLD Guidance documents, which in 2015 stated that it was 'most appropriate to treat those at greatest risk of disease complications before treating those with less advanced disease', were changed in 2016 stating that 'treatment is recommended for all patients with chronic HCV infection.' . 'Difficult-to-treat' groups such as treatmentexperienced patients, and those with cirrhosis or decompensated cirrhosis had lower SVR rates prior to 2014-2015. In 2014-2015, SVR rates for these groups were similar to those of lower risk groups, such as treatment na€ ıve patients. SVR rates for 2015 only reflect rates from the first half of the year (JanuaryJune), because of the large number of patients missing SVR data in the latter half of 2015 (insufficient time elapsed until data pull in April 2016). PEG, pegylatedinterferon; SOF, sofosbuvir, LDV/SOF; ledipasvir/ sofosbuvir; PrOD, paritaprevir/ritonavir/ombitasvir/ dasabuvir.
Questions have been raised about the feasibility of large-scale HCV treatment efforts given the high costs of new HCV medications. 38 Some have concluded that whilst eliminating chronic HCV infection is possible, the required universal access to DAAs is not currently feasible. 39 Yet, many of the obstacles of large-scale HCV treatment are not shared by the VA. It is a large, federally funded healthcare system with the ability to negotiate lower medication prices, offer DAAs to patients for free or for a nominal co-pay, obtain influxes of funding in response to demand for DAAs and identify all HCVdiagnosed patients using its comprehensive national electronic medical records. Given these advantages and our data until 2015, the possibility of near universal cure of HCV appears realisable within the VA population. Considering that HCV infection is the most common cause of cirrhosis and liver cancer in the VA and the United States, 21 that the benefits of SVR are long-lasting 40 and that HCV clearance reduces the risk of liver cancer by 76% and all-cause mortality by 50%, the potential public health benefits of large-scale HCV treatment are great. [41] [42] [43] [44] [45] [46] In addition, a recent cost-effectiveness analysis reported that DAAs must cost $47 000 per treatment course to achieve incremental cost-effectiveness ratio of $50 000 per QALY for patients with no fibrosis, 47 suggesting that it would be cost-effective or even cost saving 48 for the VA to treat all HCV-infected Veterans. 47 Another recent cost-effectiveness analysis reported that, using wholesale acquisition costs, all-oral DAA regimens such as the LDV/SOF were associated with the lowest yearly costs per SVR and was the most cost-effective option in patients with genotype 1 infection. 49 This study has a few potential limitations. SVR values were missing in 9.6% of all patients, many of whom initiated antiviral treatment in the latter half of 2015 and
had not yet accumulated sufficient follow-up time to ascertain SVR (Table S11) . Missing SVR values were imputed using era-specific logistic regression models that included multiple baseline predictors of SVR as well as duration of treatment and antiviral regimen, which increases confidence that the estimated SVR rates are accurate. The magnitude of increases in treatment and cure rates that we report in the VA may not be directly generalisable to the non-Veteran US population for many of the previously mentioned reasons including that some payers have introduced prior authorisation rules limiting HCV treatment to those with advanced liver fibrosis. 50, 51 Although we report dramatic increases in treatment rates temporally related to the introduction of DAAs and to the availability of funding for DAAs especially in 2015 (Figure 4 ), our study was not designed to formally evaluate other factors that may influence treatment rates such as staffing, infrastructure, administration, training, identification of patients and linkage to care. With the funding increases and DAA price reductions that occurred in 2016, such factors may very well become the limiting factors determining treatment rates in the near future.
In conclusion, the VA health care system has dramatically increased the number of HCV treatments initiated and resulting instances of SVR in 2015. The acceleration in treatment provision, particularly in August and September 2015, demonstrates the abilities of the VA's existing HCV treatment infrastructure when sufficient funding for DAAs is available. These results raise the spectre of near complete eradication of HCV within the VA system, which given the 124 662 VA patients with diagnosed HCV, would substantially reduce the burden of HCV within the entire country and prevent tens of thousands of deaths.
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